This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Welcome to Reed Smith's viewpoints — timely commentary from our lawyers on topics relevant to your business and wider industry. Browse to see the latest news and subscribe to receive updates on topics that matter to you, directly to your mailbox.
| less than a minute read

ACR partners to launch screening trial to determine the value of contrast-enhanced mammography for women with dense breasts

The American College of Radiology (ACR) announced this week what they call the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in collaboration with the Breast Cancer Research Foundation (BCRF) and GE Healthcare. The trial seeks to determine whether contrast-enhanced mammography (CEM) improves breast cancer detection and reduces false-positive exams in women with dense breasts.

Specifically, CMIST seeks to determine if CEM is more accurate in detecting breast cancer compared to digital breast tomosynthesis in women with dense breasts. One of the goals of the study of contrast mammography is the potential to develop more individualized breast imaging strategies for women with dense breasts, which ACR reports represents 43 percent of women aged 40 to 72. 

This is a well-timed study, given the US Food and Drug Administration's recent letter to U.S. Congresswoman Rosa DeLauro that the agency expects to finalize its breast density notification rules by year end or early next year. As a result, more women will be made aware or their breast density status -- a good outcome!

CEM combines mammography and vascular-based screening methods in a simple and quick procedure to highlight areas of unusual blood flow patterns that may indicate malignancy.


health care & life sciences, diagnostic radiology, mammography